公开(公告)号：US20220213181A1

公开(公告)日：2022-07-07

申请号：US17699925

申请日：2022-03-21

Applicant: NOVARTIS AG

Inventor： Regis CEBE ,  Igor SPLAWSKI ,  John TRAUGER ,  Andrei Igorevich VOZNESENSKY

IPC: C07K16/18 ,  C07K16/22

Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20170152313A1

公开(公告)日：2017-06-01

申请号：US15346026

申请日：2016-11-08

Applicant: NOVARTIS AG

Inventor： Kurt Alex HELDWEIN ,  Igor SPLAWSKI ,  Jennifer BROGDON ,  Joshua GOLDSTEIN ,  William DOLE ,  John TRAUGER ,  Chonghui ZHANG

IPC: C07K16/28 ,  A61K45/06 ,  A61K9/00 ,  A61K39/395

CPC classification number: C07K16/28 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07K14/4726 ,  C07K16/2851 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20240391941A1

公开(公告)日：2024-11-28

申请号：US18670859

申请日：2024-05-22

Applicant: Novartis AG

Inventor： Atwood CHEUNG ,  Donglei LIU ,  Stefan PEUKERT ,  John TRAUGER

IPC: C07F9/6561 ,  A61K31/4375 ,  A61K45/06 ,  C07D471/04

Abstract: The present disclosure relates to a compound which is a phosphoric acid ester derivative of a compound of formula (I): wherein A, L and R3 are as described herein, as well as compositions and methods of using such compound.

公开(公告)号：US20190040128A1

公开(公告)日：2019-02-07

申请号：US15971250

申请日：2018-05-04

Applicant: NOVARTIS AG

Inventor： Kurt Alex HELDWEIN ,  Igor SPLAWSKI ,  Jennifer BROGDON ,  Joshua GOLDSTEIN ,  William DOLE ,  John TRAUGER ,  Chonghui ZHANG

IPC: C07K16/28 ,  A61P9/08 ,  A61P9/12 ,  A61P9/04 ,  A61K9/00 ,  A61K39/395 ,  A61K45/06 ,  A61P9/10 ,  A61K39/00 ,  C07K14/47

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20220025344A1

公开(公告)日：2022-01-27

申请号：US17296369

申请日：2019-11-25

Applicant: NOVARTIS AG

Inventor： Jiaping GAO ,  Amitabh NIMONKAR ,  John TRAUGER ,  Andrei Igorevich VOZNESENSKY ,  Stephen Craig WELDON

IPC: C12N9/20 ,  C07K14/705 ,  A61P3/06

Abstract: This disclosure relates to fusion polypeptides comprising lipoprotein lipase (LPL) and glycosylphosphatidylinositol-anchored High Density Lipoprotein-binding protein 1 (GPIHBP1). The disclosure also relates to uses of such fusion polypeptides in treating disease such as familial chylomicronemia syndrome (FCS).

公开(公告)号：US20180044410A1

公开(公告)日：2018-02-15

申请号：US15686454

申请日：2017-08-25

Applicant: Novartis AG

Inventor： John TRAUGER ,  Andrei Igorevich VOZNESENSKY

IPC: C07K16/18

Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.